• Caffeic Acid Phenethyl Ester Inhibits C. difficile Toxins an

  2026-04-23

  Guo et al. (2025) demonstrate that caffeic acid phenethyl ester (CAPE) directly inhibits the major toxin TcdB of Clostridioides difficile and favorably alters gut microbiota in a murine infection model. This dual action highlights CAPE's promise as a lead compound for antivirulence therapy in antibiotic-resistant CDI.

• MEK1/2-c-Myc:MAX Axis Prevents Polycomb Repression of TERT i

  2026-04-22

  This study reveals a cooperative mechanism between MEK1/2 kinases and the c-Myc:MAX complex that safeguards TERT transcription in human pluripotent stem cells by preventing PRC2-mediated chromatin repression. The findings clarify how MEK-ERK pathway activity maintains telomerase expression, with implications for stem cell biology and targeted pathway inhibition research.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Workflo

  2026-04-22

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, empowers researchers to dissect the ubiquitin-proteasome system and modulate NF-κB signaling with high specificity. This guide translates primary literature and advanced protocols into actionable workflows, bridging inflammation, apoptosis, and tumor immunity research.

• Translating TGF-β Dual Inhibition: Strategy and Mechanism wi

  2026-04-21

  A thought-leadership article for translational researchers, dissecting the mechanistic and strategic advantages of dual TGF-β receptor inhibition using LY2109761. This piece integrates recent advances in the molecular understanding of TGF-β-mediated cytostasis, the role of Smad2/3 phosphorylation, and the translational relevance of targeting the TGF-β pathway in cancer and fibrosis models. With protocol guidance, evidence-backed insights, and a vision for future research, this article positions LY2109761 (TβRI/II kinase inhibitor) from APExBIO as a pivotal tool for advancing preclinical and translational studies.

• HOBt (1-Hydroxybenzotriazole): Expanding Peptide Synthesis H

  2026-04-21

  Discover how HOBt (1-Hydroxybenzotriazole) enables advanced peptide synthesis and amide bond formation while minimizing epimerization. This article explores mechanistic insights, protocol optimization, and the future of racemization control, offering unique scientific depth beyond standard workflows.

• M344: Histone Deacetylase Inhibitor for Advanced Cancer Rese

  2026-04-20

  M344 stands apart as a potent, cell-permeable histone deacetylase inhibitor, enabling precise epigenetic modulation in diverse cancer models and HIV-1 latency workflows. This article guides researchers through practical applied protocols, troubleshooting, and comparative advantages, leveraging robust evidence and APExBIO’s trusted supply chain.

• Angiotensin II in Vascular Remodeling & Aneurysm Research

  2026-04-20

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) enables precise modeling of hypertension and aortic aneurysm mechanisms, thanks to its robust GPCR agonist activity. Leveraging APExBIO's validated peptide, researchers can replicate vascular remodeling and smooth muscle cell hypertrophy workflows with high reproducibility, directly informed by cutting-edge multiomics studies.

• Drosophila Keap1 Nuclear Condensates in Oxidative Stress Res

  2026-04-19

  This study uncovers the mechanism by which Drosophila Keap1 (dKeap1) forms nuclear condensates in response to oxidative stress, highlighting the essential roles of its N- and C-terminal domains and intrinsically disordered regions. These findings advance our understanding of Keap1-Nrf2 signaling in chromatin regulation and offer new perspectives for studying phase separation in stress adaptation.

• Novobiocin Synergy: Advanced Antimicrobial Strategies and Me

  2026-04-18

  Discover the unique antimicrobial mechanisms of Novobiocin, a potent aminocoumarin antibiotic, and how synergy with lactoferrin is reshaping antibacterial and antiparasitic research. This article delivers in-depth, evidence-based analysis unavailable in other reviews.

• AZD0156: ATM Kinase Inhibitor Workflows for Cancer Research

  2026-04-17

  AZD0156 stands out as a highly selective ATM kinase inhibitor, empowering cancer research with precision-targeted disruption of DNA damage response and checkpoint control. This guide delivers workflow-optimized protocols, advanced troubleshooting, and comparative insights to maximize translational impact using APExBIO's trusted reagent.

• ARCA EGFP mRNA: Reliable Reporter for Fluorescence Assays

  2026-04-16

  This article analyzes real-world workflow challenges in cell viability and transfection assays, demonstrating how ARCA EGFP mRNA (SKU R1001) addresses reproducibility and sensitivity demands. Drawing on peer-reviewed findings and validated protocols, we provide scenario-driven guidance for optimal use of this direct-detection reporter mRNA in mammalian cell gene expression studies.

• SGI-1027 and Everolimus Synergize via Lysosomal Disruption i

  2026-04-15

  This study reveals that the methuosis inducer SGI-1027 enhances the efficacy of everolimus in renal cell carcinoma by promoting apoptosis and GSDME-dependent pyroptosis through lysosomal membrane permeability. The findings offer a novel approach to overcoming drug resistance in advanced RCC and suggest new combinatorial therapeutic strategies.

• miR-196a Drives Aggressive EAC via c-Myc/TERT/NFκB Axis Disr

  2026-04-14

  This study elucidates how microRNA-196a enhances esophageal adenocarcinoma (EAC) aggressiveness by upregulating the c-Myc/TERT/NFκB pathway, promoting epithelial-to-mesenchymal transition and tumor progression. These mechanistic insights highlight new intervention points for targeted cancer research.

• Gefitinib (ZD1839): Applied EGFR Inhibition in Tumor Assembl

  2026-04-13

  Leverage Gefitinib (ZD1839) to unlock precision EGFR pathway inhibition in next-generation tumor assembloid systems. This guide distills advanced workflows, troubleshooting tips, and actionable protocol enhancements for dissecting drug response and resistance in physiologically relevant cancer models.

• MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliu

  2026-04-12

  Unlock reproducible, high-sensitivity cell viability assays with MTT, the gold-standard tetrazolium salt for metabolic activity measurement. This article bridges advanced protocol design with troubleshooting expertise, inspired by novel chemoradiation research and APExBIO’s ultra-pure MTT reagent.

16434 records 1/1096 page Next 12345 下5页 Last page